TY - JOUR
T1 - A case of recurrent cutaneous Mycobacterium chelonae infection after treatment
AU - Eto, Ayaka
AU - Nakamura, Misa
AU - Ito, Saori
AU - Tanaka, Maya
AU - Tsuji, Gaku
AU - Matsuda, Tetsuo
AU - Furue, Masutaka
PY - 2018
Y1 - 2018
N2 - Mycobacterium chelonae (M. chelonae) is widely distributed in the environment and particularly infects immunosuppressed patients. Its infection is characterized by various and multiple cutaneous lesions. In the present case, an elderly patient with long-term use of immunosuppressive agents had a relapse of cutaneous M. chelonae infection 8 months after treatment. This case was considered to involve latent infection of M. chelonae that developed resistance to antibiotics. Cutaneous M. chelonae infection has often been treated by antibiotic monotherapy. However, some cases that developed resistance to clarithromycin, a key drug for treating this infection, have been reported, so it is recommended that treatment proceed via a combination of antibiotics. Case reports of cutaneous M. chelonae infection are increasing, so further studies on the choice of antibiotics, and the duration and endpoint of treatment are required.
AB - Mycobacterium chelonae (M. chelonae) is widely distributed in the environment and particularly infects immunosuppressed patients. Its infection is characterized by various and multiple cutaneous lesions. In the present case, an elderly patient with long-term use of immunosuppressive agents had a relapse of cutaneous M. chelonae infection 8 months after treatment. This case was considered to involve latent infection of M. chelonae that developed resistance to antibiotics. Cutaneous M. chelonae infection has often been treated by antibiotic monotherapy. However, some cases that developed resistance to clarithromycin, a key drug for treating this infection, have been reported, so it is recommended that treatment proceed via a combination of antibiotics. Case reports of cutaneous M. chelonae infection are increasing, so further studies on the choice of antibiotics, and the duration and endpoint of treatment are required.
UR - http://www.scopus.com/inward/record.url?scp=85064531712&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064531712&partnerID=8YFLogxK
U2 - 10.2336/nishinihonhifu.80.546
DO - 10.2336/nishinihonhifu.80.546
M3 - Article
AN - SCOPUS:85064531712
SN - 0386-9784
VL - 80
SP - 546
EP - 549
JO - Nishinihon Journal of Dermatology
JF - Nishinihon Journal of Dermatology
IS - 6
ER -